At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis
In Brief
A Phase 2 clinical trial evaluating Placebo and CFZ533 for Myasthenia Gravis, Generalized. Completed, enrolled 44 participants across 15 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis, Generalized
CountriesCanada, Denmark, Germany, Russia, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedOct 2015
Primary CompletionJul 2017
Study CompletionDec 2017
TodayJul 2026
First PostedOct 1, 2015
Enrollment StartSep 29, 2015
Primary CompletionJul 31, 2017
Study CompletionDec 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.8 years ago
Interventions
Placebodrug
CFZ533drug